INHIBITORS OF DUAL LEUCINE ZIPER (DLK) KINASE FOR THE TREATMENT OF DISEASE
    2.
    发明申请
    INHIBITORS OF DUAL LEUCINE ZIPER (DLK) KINASE FOR THE TREATMENT OF DISEASE 审中-公开
    双亮氨酸拉链(DLK)激酶抑制剂用于治疗疾病

    公开(公告)号:WO2018044808A1

    公开(公告)日:2018-03-08

    申请号:PCT/US2017/048941

    申请日:2017-08-28

    Abstract: Disclosed herein are compounds which inhibit the kinase activity of dual leucine zipper (DLK) kinase (MAP3K12), pharmaceutical compositions, and methods of treatment of DLK-mediated diseases, such as neurological diseases that result from traumatic injury to central nervous system and peripheral nervous system neurons (e.g. stroke, traumatic brain injury, spinal cord injury), or that result from a chronic neurodegenerative condition (e.g. Alzheimer's disease, frontotemporal dementia, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, spinocerebellar ataxia, progressive supranuclear palsy, Lewy body disease, Kennedy's disease, and other related conditions), from neuropathies resulting from neurological damage (chemotherapy -induced peripheral neuropathy, diabetic neuropathy, and related conditions) and from cognitive disorders caused by pharmacological intervention (e.g. chemotherapy induced cognitive disorder, also known as chemobrain).

    Abstract translation: 本文公开了抑制双亮氨酸拉链(DLK)激酶(MAP3K12)的激酶活性的化合物,药物组合物以及治疗DLK介导的疾病例如由创伤引起的神经疾病的方法 中枢神经系统和外周神经系统神经元损伤(例如中风,创伤性脑损伤,脊髓损伤)或由慢性神经变性疾病(例如阿尔茨海默氏病,额颞叶痴呆,帕金森病,亨廷顿病,肌萎缩侧索硬化,脊髓小脑 共济失调,进行性核上性麻痹,路易体疾病,肯尼迪氏病和其它相关病症),神经病损伤(化学疗法诱导的周围神经病,糖尿病性神经病和相关病症)和由药理学干预(例如化学疗法 诱导认知障碍,也称为化学细胞)。

Patent Agency Ranking